US Patent

US8211880 — Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Method of Use · Assigned to Alcon Research LLC · Expires 2029-03-10 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a low-viscosity, highly flocculated triamcinolone acetonide suspension suitable for intravitreal injection.

USPTO Abstract

Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Drugs covered by this patent

triamcinolone-acetonide (TRIAMCINOLONE ACETONIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1258`	—	triamcinolone-acetonide

Patent Metadata

Patent number: US8211880
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-10
Drug substance claim: No
Drug product claim: No
Assignee: Alcon Research LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.